布地奈德福莫特罗对轻中度支气管哮喘患者预后及通气功能的影响

Influence of budesonide and formoterol on the prognosis and ventilatory function in patients withmild-to-moderate bronchial asthma

目的评价布地奈德福莫特罗对支气管哮喘急性发作轻中度患者预后与肺通气功能的影响。方法选取176例支气管哮喘急性发作轻中度患者，根据随机数字表法分为治疗组与对照组，每组88例。治疗组给予布地奈德福莫特罗粉雾吸入剂治疗，同时口服孟鲁司特片；对照组口服强的松片，并同时给予茶碱缓释胶囊与孟鲁司特片治疗。所有患者均治疗5 d。记录两组患者治疗前后急性哮喘生活质量问卷评分（AQLQ）、呼气流速峰值占预计值的百分比（PEF%pred）、第1秒用力呼气量（FEV1）与血氧饱和度（SpO2），观察两组患者不良反应发生情况。结果两组患者治疗后急性AQLQ评分及SpO2、PEF%pred、FEV1指标均较治疗前显著改善（P均〈0.05）。与对照组比较，治疗组不良反应发生率（0）低于对照组（29.5%），差异有统计学意义（χ2＝30.507，P〈0.01）。结论布地奈德福莫特罗治疗轻中度哮喘急性发作，可以显著改善患者预后与肺通气功能，用药安全性好，值得临床推广应用。

Objective To evaluate the influence of budesonide and formoterol on the prognosis and pulmonary ventilation function in patients with mild-to-moderate bronchial asthma. Methods One hundred and seventy-six patients with mild or moderate acute bronchial asthma were selected and were randomly divided into treatment group and control group according to the random number table method, with 88 cases in each group. Patients in treatment group were treated with budesonide and formoterol powder inhalation, at the same time, administrated montelukast. Patients in control group orally took prednisone tablets and were treated with theophylline sustained release capsules and montelukast. All pa- tients were treated for 5 days. Before and after treatment, asthma quality of life questionnaire （AQLQ） scores, percentage of peak expiratory flow rate in the predicted value （ PEF% pred） , forced expiratory volume in 1 s （FEV1） and oxygen saturation （SpO2 ） in the two groups were recorded. The incidence of adverse reactions was observed. Results The AQLQ scores and the indexes of SpO2, PEF% pred and FEV1 in the two groups were all significantly better than those before treatment （ all P 〈 0.05 ）. The inci- dence of adverse reactions in treatment group （0） was significantly lower than that in control group （29.5%）, the difference was statistically significant （ χ2 = 30. 507, P 〈 0. 001 ）. Conclusions The application of budesonide and formoterol in patients with acute exacerbation of mild-to-moderate asthma can significantly improve the prognosis and pulmonary ventilation with high safety, and it is worthy of clinical application.